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Abstract
BACKGROUND: The lack of anatomical details in standard 131Io-
dine whole body scanning (131I WBS) interferes with the proper
localization of metastatic differentiated thyroid carcinoma (DTC)
lesions. In addition, nearby or overlapping variable physiologi-
cal distribution of 131I may affect the specificity of 131I uptake,
giving indeterminate results. The aim of this study was to dem-
onstrate the clinical usefulness of simultaneous co-registration
of 99mTc MDP bone scanning as an anatomical landmark with
131I scanning in the evaluation of metastatic DTC.
MATERIAL AND METHODS: Twenty-five patients (16 females
and 9 males, mean age ± SD = 52 ± 13 years) with meta-
static DTC (17 papillary, 8 follicular), were included. Whole
body scanning using a 256 ¥ 1024 matrix and an 8 cm/min
scan rate were obtained 48 hours after oral administration of
185–370 MBq 131I and 2 hours after IV administration of 185–
–370 MBq 99mTc MDP using a dual head gamma camera
equipped with high energy parallel hole collimators. Occa-
sionally, additional simultaneous co-registration of localised
detailed images was also performed using a 256 ¥ 256 ma-
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trix size. The two planar images were fused with optional fu-
sion of SPECT images.
The data from standard 131I scanning and fused 131I/ 99mTc-MDP
scanning were separately assessed by two nuclear medicine
physicians. Fusion images were considered to improve image
interpretation in comparison with standard 131I scanning when
they provided better localization of lesions.
RESULTS: All lesions in the present study were validated by
radiological images and clinical follow up for at least 12 months.
Forty-eight metastatic lesions were confirmed as follows: 2 in
the skull, 10 in the neck, 20 in the thorax, 12 in the pelvic-ab-
dominal region and 4 in the extremities. Standard 131I WBS
showed 54 extra-thyroidal foci with 8 false positive lesions of
which 2 were located in the scalp and 6 in the pelvic-abdominal
region extra-skeleton (i.e. sensitivity 100%, specificity 86%). Out
of the 48 validated lesions, 16 were indeterminately localized:
10 in the thorax (3 mediastinal nodal lesions, 5 vertebral lesions
and 2 ribs) and 6 in the pelvic-abdominal region (2 upper sac-
ral, 2 sacroiliac region and 2 ischial bone). Fusion images con-
firmed the precise localization of the pathological uptake in the
validated 48 lesions (sensitivity 100%, specificity 100%). There
were 2 (4%) indeterminate lesions in fused planar imaging that
were clearly localized via fused SPECT images.
CONCLUSIONS: Fusion images using simultaneous co-regis-
tration of 131I and 99mTc MDP scanning is a simple and feasible
technique that improves the anatomically limited interpretation
of scintigraphy using 131I alone in patients with metastatic differ-
entiated thyroid carcinoma. The diagnostic advantage of this
technique seems to be more apparent in the thoracic and pel-
vic-abdominal regions in contrast to the neck and extremities.
Key words: simultaneous Co-registration, differentiated
thyroid carcinoma, Iodine-131 scan, technetium-99m-MDP
bone scan
Introduction
Differentiated thyroid cancer (DTC) is a common endocrine
cancer and is reported as one of the most escalating human can-
cers [1]. DTC is an indolent tumour with a high chance of defini-
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tive cure due to its low metastatic potential. The high grade of
differentiation and appropriate treatment with 131Iodine therapy has
lead to a long-term survival exceeding 90% [2]. A small propor-
tion of patients (5–20%) with unfavourable prognostic risk factors
will develop local or distant metastases, and when distant me-
tastases are present, the overall survival rate declines to 40% af-
ter ten years. The metastatic sites are frequently the regional lymph
nodes, followed in frequency by metastases to the lungs and the
skeletal system [3–6]. The aim of post-surgical follow up is the
early detection of metastases especially those that can lead to
respiratory failure, airway obstruction and neurological complica-
tions that are considered major causes of death in DTC. Regular
follow up with whole body iodine scanning and other functional
and conventional imaging will improve the management and quality
of life in a disease with known low intrinsic mortality rate [7].
Conventional imaging modalities used for follow up of DTC
include ultrasonography for cervical lymph nodes, CT for lung me-
tastases and MRI for brain lesions. However, 131I whole-body scan
(WBS) represents a cornerstone in routine follow up of these pa-
tients. The ability of thyroid malignant cells to trap and organify
the iodine through the sodium-iodine symporter is the basis for
the diagnostic and therapeutic use of 131I [8]. The identification of
abnormal areas of iodine uptake in the follow-up studies is the
strongest evidence of metastases or recurrence. On the other
hand, 131I WBS has several limitations that interfere with its clinical
value. The long half-life (8 days) and the sub-optimal physical
characteristics (high gamma ray energy of 364 Kev), limit the ad-
ministrated dose significantly, leading to poor image quality. This
leads to poor anatomical localisation of the abnormal foci seen
on 131I WBS. Moreover, 131I is physiologically secreted in the sali-
vary glands, stomach, gut and urinary tract leading to overlap and
uncertainty in the identification of abnormal pathological meta-
static foci. [9,10].
Proper anatomical localization in nuclear medicine imaging is
an inherited problem that has encouraged multi-modality imag-
ing with special fusion algorithms [11, 12]. Recently, hybrid scan-
ners using SPECT or PET in combination with CT were introduced
with great potential. Yet, the high technical demands and the high
cost of these machines limit their availability. One particular prob-
lem regarding the modality of these hybrid scanners (SPECT/CT
or PET/CT) in DTC patients is the need to avoid contrast agents
for the CT part. Contrast agents (with high iodine content) will
interfere with the future administration of radioiodine for diagnos-
tic or therapeutic purposes for a variable period of time.
99mTc-methylene diphosphonate (99mTc-MDP) is commonly
used for the detection of suspected skeletal metastases in pa-
tients with DTC. Bone scintigraphy represents an excellent meth-
od for visualizing the whole skeleton with great anatomical orien-
tation. In a preliminary work, the usefulness of the addition of 99mTc-
MDP bone scan to 131I whole body scintigraphy for better anatom-
ical localisation of bone metastases in DTC has been reported
[13, 14]. However, such studies lack the technical details of these
different scintigraphic techniques, particularly regarding the ac-
quisition and processing of details.
The aim of the current work was to demonstrate the technical
details of simultaneous acquisition of 99mTc-MDP bone scanning
and 131I whole body scanning, and secondly, to show the incre-
mental clinical usefulness of combined co-registered images from
both 99mTc-MDP and 131I for the accurate detection of local and
distant metastases from DTC.
Material and methods
The study was approved by the Committee Board of Radio-
therapy and Nuclear Medicine department at the National Cancer
Institute, Cairo. Informed consent was obtained from all patients
and/or their relatives, with a complete description of the proce-
dures. The work involved twenty-five patients with metastatic DTC
(16 females and 9 males), average age  52 ± 13 years. Histolog-
ically, there were 17 patients with papillary DTC and 8 patients
with follicular DTC. All patients had thyroidectomy (near-total in 10
and total thyroidectomy in 15). Detailed patient characteristics are
presented in Table 1. All cases had metastatic disease and the
metastases were defined based on the appearances on neck ul-
trasound, CT, MRI and 131I WBS. In addition, increased Thyroglo-
bulin (Tg) levels, histological findings and evolution of the disease
during subsequent follow up for at least 12 months were consid-
ered to confirm the presence of metastases.
Scintigraphic procedures
The patients’ TSH levels were assayed 4-6 weeks after thy-
roidectomy during which thyroid hormone replacement was with-
held. The patients were considered legible for 131I diagnostic WBS
when TSH was > 30 Iu/ml. The patients were then given a dose of
5 mCi 131I orally and imaged 48–72 hours later.
Acquisition
The initial acquisition of 131I WBS was performed using a large
field of view gamma camera (E-cam Dual head-Siemens) fitted
with a high-energy parallel-hole collimator. The photo-peak was
364 keV with symmetrical 20% window. The whole-body scan was
done with a table speed of 6 cm/min. The next step on the imag-
ing day was to intravenously inject the patient with 5 mCi of 99mTc-
MDP and image after 2–3 hours.
Fused 99mTc-MDP / 131I-WBS scanning
The fusion scan acquisition started 2–3 hours post 99mTc-MDP
injection using the same camera equipped with high-energy paral-
lel-hole collimators. This acquisition was simultaneous using two dif-
ferent windows (15% window centred on 364 keV for 131I and 15%
window centred on 140 keV for 99mTc-MDP). The matrix resolution
used in this fusion scan was 256 ¥ 1024 and the table speed was 8
cm/min. In some patients, additional spot views in fusion mode (ma-
trix 256 ¥ 256), were acquired for more anatomical delineation. Op-
tionally, SPECT images were obtained with dual-energy windows, 32
projections for each detector and a matrix resolution of 64 ¥ 64.
Table 1. Patient characteristics
PTC FTC
Number (n) 17 8
Age: Years (mean ± SD) 48.8 ± 12 55 ± 15
Female: male 1.9:1 1.6:1
Thyroidectomy 17/17 8/8
PTC — papillary thyroid carcinoma; FTC — follicular thyroid carcinoma; SD — standard
deviation
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Data processing and image fusion
The planar data provide two simultaneously co-registered sep-
arate images with two different count intensity scales. Processing
entails successful fusion of these tow images with preservation of
the data from the two scale producing single scale image that
maintain high target to background (T/B) ratio. This is obtained by
tuning the intensity of 131I images using variable multiplication fac-
tor (K) for 131I matrix to approximate the count intensity of the
99m Tc-MDP image. This count-intensity tuned image will be sum-
mated to the bone-scan image providing a single-scale image
with satisfactory T/B ratio.
Images analysis and interpretation
Two experienced nuclear medicine physicians were respon-
sible for visual interpretation of the images on a lesion-by-lesion
basis for detection of metastases in lymph nodes, lungs, bones
and other regions. The findings were defined as positive or nega-
tive based on consensus.
The 131I WBS and fusion scintigraphy were interpreted inde-
pendently of each other, then all the images were re-evaluated
based on the fusion images including knowledge of the results of
the 131I-WBS scintigraphy.
The usefulness of fusion scintigraphy was assessed based
on whether:
— fusion scintigraphy provided additional anatomical information
that solves the problem of indeterminate lesions on 131I-WBS;
— fusion scintigraphy provided additional anatomical informa-
tion that changed the previous staging of the patient, based
on the 131I-WBS alone;
— fusion SPECT scintigraphy provided more detailed informa-
tion than the planar fusion scintigraphy.
Results
The total number of definite metastases was 48 lesions. The
highest distribution of metastatic lesions was in the lungs, bones
or both, with a frequency of 10 (21%), 8 (16%) and 22 (46%),
respectively. Nodal metastases were found in 8 cases (16%).
Metastatic lesions were 27/48 (56%) from papillary DTC and 21/
/48 (44%) from follicular DTC. The details of the distribution and
frequency of these metastatic lesions are shown in Table 2.
Regional anatomical distribution of metastatic lesions showed
that the highest number 20/48 (42%) was present in the thoracic
region, and the lowest was in the head region 2/48 (4%). Variable
anatomical distribution was seen in the neck, extremities and pel-
vic-abdominal areas, as shown in Table 3.
131I whole body scintigraphy (131I-WBS)
There were 56 areas of focal uptake on 131I WBS. All metastatic
lesions showed positive focal uptake on the 131I Whole Body Scan
(WBS) with a sensitivity of 100%. However, an additional eight false-
positive focal areas were seen reducing the specificity to 86%.
Findings in 131I-WBS were divided into two groups. Group A,
Positive 131I metastatic lesions that are well localized anatomically,
which included 32 lesions (67%). Group B, are the 131I metastatic
lesions that are anatomically indeterminate, which included 16/48
lesions (33%) and included 10 lesions in the thorax and 6 in the
pelvi-abdominal region.
131I-WBS and 99mTc-MDP bone scan fusion
scintigraphy
As indicated in Table 4, the addition of bone scintigraphy and
the resultant fusion (131I and MDP) scintigraphy correctly identified
48 metastatic lesions out of the 56 131I positive lesions. The re-
maining eight 131I focal areas that were seen in 131I-WBS but not
anatomically defined by 99mTc-MDP bone scan were located in
the scalp, large bowel and pelvic regions. Accordingly, these were
considered false positive findings by 131I WBS. The remaining 48
lesions were considered true positives, and, therefore, the speci-
ficity of the fusion scan was 100%.
In group A, fusion scintigraphy confirmed the 131I findings with
concordant agreement between both 131I and fusion scan of 100%.
In group B, out of 16 anatomically indeterminate lesions, planner
fusion scans localized 14 lesions accurately (87%). The other two
Table 2. Sites of metastases from DTC
Site of metastases Overall PTC FTC
(n = number) (n = 48) (n = 27) (n = 21)
Nodal 8 6 2
Lungs 10 6 4
Bones 8 3 5
Lungs and bones 22 12 10
PTC — papillary thyroid carcinoma; FTC — follicular thyroid carcinoma
Table 3. Distribution of metastases by region
Region of metastases Overall PTC FTC
(n = 48) (n = 27) (n = 21)
Skull 2 1 1
Neck 10 7 3
Thorax 20 12 8
Pelvi-abdominal 12 6 6
Extremities 4 1 3
PTC — papillary thyroid carcinoma; FTC — follicular thyroid carcinoma
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lesions were clearly identified by SPECT of fused 131I and MDP
scintigraphy and were in the thorax and pelvi-abdominal regions.
Table 5 shows the effect of fused planner 131I/99mTc-MDP scans in
the identification of indeterminate lesions by standard 131I WBS.
Change in management
Change in management of patients occurred in 3/8 patients
who had false-positive findings by 131I-WBS alone. Of those three
patients, one had false positive scalp lesion, and the other 2 pa-
tients had false-positive colonic activity. Those three patients were
down-staged from distant metastases to local metastases, as they
already had involved cervical lymph node metastases.
Discussion
The early detection of recurrence and/or metastases is essen-
tial for further management in DTC. Following thyroidectomy and
post surgical ablation, periodic follow up with 131I WBS remains a
reliable test for the management of DTC patients. The presence of
pathological foci of 131I accumulation in the neck, chest or skeletal
system is strong evidence for recurrence or metastases [13, 15–
–17]. However, several inherent limitations remain challenging and
influence the reliability of this technique. One notable limitation is
the physiological secretion and excretion of 131I from the salivary
glands, stomach, bowel and urinary system, which are considered
the most common causes of false-positive results. Moreover, ac-
cumulation of 131I in some inflammatory conditions, especially in
bowel and lungs with variable rate of turnover, is not uncommon.
This may provide a potential source of error when misinterpreted
as positive for DTC. The limited anatomical information from this
functional technique has a major impact in this misinterpretation
and in many instances provides indeterminate results [18, 19].
Recently the effectiveness of simultaneous dual isotope co-
registration using a combination of 99mTc-MDP diphosphonate and
131I scanning for localization of metastases of DTC has been re-
ported. 99mTc-MDP scans can provide an internal anatomical land-
mark that, when fused with 131I scanning, can help in the localiza-
tion of iodine-avid foci. However, these reports did not show the
technical details of the fusion process [20, 14].
The aim of this technique is to fuse two simultaneously co-
registered images with two different intensity scales yielding a sin-
gle scale intensity image that preserves the data of the two scales
with a high T/B ratio. There are several factors that should be con-
sidered with this technique, including: using single energy line
isotopes, adequate  energy gap between the two energy windows
to limit cross talking, proper selection of collimator (use a higher
energy collimator to reduce penetration of collimator septa), use
of high-speed detector electronics (i.e. fast response time to en-
hance count efficiency) and finally consider the quantity of used
radio-activity for each isotope to create a balance in the count
collected for each study.
Based on the above-mentioned considerations, we used a
high-energy collimator and limited the injected dose of 99Tc-MDP
to 185–370 MBq, as the bone scanning was considered only as
an anatomical landmark. This may yield a sub-optimal bone scan
quality but avoids acquiring too much count from the scale of
bone display, which may obscure the iodine-avid lesions and fa-
Table 3. Distribution of metastases by region
Region of metastases Overall PTC FTC
(n = 48) (n = 27) (n = 21)
Skull 2 1 1
Neck 10 7 3
Thorax 20 12 8
Pelvi-abdominal 12 6 6
Extremities 4 1 3
PTC — papillary thyroid carcinoma; FTC — follicular thyroid carcinoma
Table 4. Findings of standard I-131 and fused I-131 / MDP bone
scans
Standard I-131 Fused I-131/ MDP scans
(n = 56)  (n = 48)
TP 48 48
FP 8 0
Sensitivity 100% 100%
Specificity 86% 100%
TP — true positive, FP — false positive, n — number of patients
Table 5. Effect of fused planner I-131/MDP scans in identification of indeterminate lesions
Indeterminate lesions Effect of planar fusion scan
Number of lesions Decrease with I-131/MDP (%)
 I-131 I-131/MDP
(n = 16) (n = 2)
Thorax 10 1 90%
Pelvic-abdominal 6 1 83%
Skull, neck 0 0 0%
Extremities 16/48 2/48
Total 33% 4% 29%
n — number of patients. Fused SPECT images clarify the 2 indeterminate lesions of fused planar images
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cilitates the process of fusion with a satisfactory T/B ratio. There-
fore, the sensitivity of 99mTc-MDP bone scan in the detection of
DTC was relatively underestimated (40%) compared to other re-
ports (60%) [21, 20].
Tuning between the two images with different count intensity
scales was done through the use of variable multiplication factor
(K) for 131I image matrix before matrix summation, which yields
a satisfactory fused image with a single intensity scale and pro-
vides a reasonable T/B ratio (Figure 1). This process of matrix mul-
tiplication and image summation is not applicable for fused SPECT
images because separation between the acquired SPECT data in
two different scales, one for each isotope, is not possible. Howev-
er, the relatively limited injected dose of 99mTc-MDP and collection
of data through 360 degree around the object create a reasonable
balance between T/B ratio after reconstruction (Figures 2, 3).
DTC has been reported to be 2–4 times more frequent in fe-
males than in males although the rate is lower for patients with
distant metastases [22]. In our study, where all patients had me-
tastases of DTC, the female: male ratio was 1.9:1 for PTC and
1.6:1 for FTC, further supporting the higher relative risk of distant
metastases among males [23]. Similar to other results [24, 6, 25],
in the present study FTC was more frequent in males and had
a higher rate of metastatic potential compared to PTC (21 meta-
static lesions/8 FTC patients compared to 27 metastatic lesions
for 17 PTC patients). The distribution by sites for distant metastases
corresponded to the results of other studies [3, 4].
In practice, indeterminate localization of iodine-avid foci in 131I
WBS requires complementary morphological imaging modalities
(U/S, CT and/or MRI) for clarification. While these techniques pro-
vide excellent anatomical information compared to functional nu-
clear medicine imaging, they have some diagnostic limitations.
These limitation include the inability to detect disease in lymph
nodes (LNs) that are not or are only slightly enlarged (sub-centi-
metre nodes), differentiation of scar tissue or fibrosis from local
recurrence, and the limited ability in monitoring the response to
therapy. Moreover, the difference in the mechanisms of assess-
ing malignancy with functional vs. anatomical imaging creates
some discrepancy in their results. Another limiting factor is the
Tc−99m MDP bone scan Iodine WBS
Figure 1. The difference in intensity scales and count per pixel for 99mTc-MDP and 131I scans. A. Figure shows the difference in count intensity between
bone and iodine scan intensity; B. Figure shows the difference between count per pixel for iodine and bone scale. Image manipulation entails the use of
variable multiplication factor (K) for I-131 image followed by summation of iodine and bone scan images producing fused image with single intensity scale.
A B
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use of CT with contrast, which limits further radioiodine adminis-
tration [14, 19, 26, 27].
The clinical usefulness of using a combination of 99mTc-MDP
and 131I scanning for localization of metastases from DTC has been
previously described by Johann Schoenberger and colleagues
[14]. They gained additional information in 16 of 21 patients be-
cause the presence of osseous structures from bone scintigra-
phy facilitates the correct diagnosis of the lymph node involved;
the identification of distant metastases and delineation of residual
thyroid tissue from lymph node metastases after thyroidectomy.
In the present study, simultaneous co-registered fused 131I/99m
Tc-MDP scanning was able to depict eight false positive iodine-
avid foci in standard 131I WBS. Most of these foci were linked to
persistent focal colonic activity located in the pelvic-abdominal
region. Therefore, the specificity of the simultaneous co-registered
combined 131I/99mTc-MDP was 100% compared to 86% for stan-
dard 131I. This resulted in disease down-staging in three patients
and a change in the strategy of therapy.
The present study shows concordant agreement between both
standard 131I and fusion planar scans in 32 out of 48 (67%) le-
sions. Concordant results were higher in the skull, neck and ex-
tremities compared to the thoracic and pelvic-abdominal regions.
On the other hand, the planar fused scans provided additional
anatomical information in 87% of indeterminate lesions by outlin-
ing bones. Fused SPECT images improved the detectability of
two indeterminate lesions in fused planar images by providing
Figure 2A. 131I WBS and bone performed for 48-year-old male patient with metastatic disease before fusion FCT. Out of the three who demonstrated hot
foci in 131I, two were indeterminately localized, one was located in the thoracic region and the other was located in the pelvic region.
B. Figure shows multi-spot anterior and posterior planar views before and after fusion. The fused planar images clearly identify the location of hot foci in
left ribs posteriorly as well as left ala close to tip of sacro-iliac region.
Anterior Posterior Anterior Posterior
I−131 planar view Tc−99m bone scan
Anterior Posterior
Fused scan I−131 planar spot view
Fused planar scan
I−131 WBS Tc−99m DP bone scan
A
B
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more anatomical information with better contrast enhancement
and solved the problem of overlapping structures.
We have shown, in selected cases, that fusion scintigraphy
using the mentioned simultaneous co-registration of 131I/99mTcM-
DP method is helpful in the localization of pathological tracer ac-
cumulation through delineation of intra- and extra-osseous foci.
Moreover, simultaneous acquisition of both nuclides excludes
patient motion artefact and facilitates fusion processing and ma-
nipulation.
Recently, newly developed machines that combined CT and a
gamma camera (SPECT/CT) were introduced and showed great
potential. The combination of functional imaging with the anatomi-
cal details of multi-slice CT represents the best solution in cases
involving metastatic DTC. However, the high cost of this machine
and limited availability interferes with the wide distribution of this
advanced technology. In addition, contrast related technical prob-
lems remain challenging, particularly in DTC patients, as they inter-
fere with further administration of radioiodine in those patients. There-
fore, fused scintigraphy offers an effective existing alternative tech-
nique that is available in many nuclear medicine departments.
Conclusions
Fusion imaging using simultaneous co-registration of 131I and
99mTc MDP scanning is a simple and feasible technique that im-
proves the anatomically limited interpretation of scintigraphy us-
ing 131I alone, in patients with metastatic DTC. Simultaneous ex-
ploration of osseous structures and areas of high 131I uptake in
Anterior Posterior Anterior Posterior Anterior Posterior
Bone scan I−131 WBS Fused scans
Le
ft
An
t
Le
ft
Figure 3A. 99mTc-MDP bone scan (left column), standard 131I WBS (middle column) and fused scans (right column) in a female patient with multiple
metastatic hot foci. The planar fused image cannot clarify totally the indicated intra-thoracic lesion because of overlapping structures.
B. Reconstructed transverse, sagittal and coronal slices for thoracic region for the same patient showing the hot foci to be nodal mediastinal lesion.
A
B
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fused scintigraphy allow clear delineation of osseous and extra-
osseous foci. Moreover, the added anatomical information from
fused scans significantly reduces false positive and indeterminate
results. The diagnostic advantage of this technique seems to be
more apparent in the thoracic and pelvi-abdominal regions than
in the neck and extremities.
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